Childhood Cancer Drugs for the World

Author(s):  
A. R. Volkova ◽  
Kh. M. Vakhitov ◽  
E. V. Kumirova

Malignant neoplasms occupy one of the leading places in the structure of infant mortality. This article provides an overview of current information on the epidemiological features and systems of cancer accounting in children in Russia and the world. The described methodologies for reporting cases of childhood cancer in developed countries can serve as a guideline for improving the domestic pediatric oncology service.


Toxins ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 765
Author(s):  
Monika Urbaniak ◽  
Agnieszka Waśkiewicz ◽  
Łukasz Stępień

Most of the fungi from the Fusarium genus are pathogenic to cereals, vegetables, and fruits and the products of their secondary metabolism mycotoxins may accumulate in foods and feeds. Non-ribosomal cyclodepsipeptides are one of the main mycotoxin groups and include beauvericins (BEAs), enniatins (ENNs), and beauvenniatins (BEAEs). When ingested, even small amounts of these metabolites significantly affect human and animal health. On the other hand, in view of their antimicrobial activities and cytotoxicity, they may be used as components in drug discovery and processing and are considered as suitable candidates for anti-cancer drugs. Therefore, it is crucial to expand the existing knowledge about cyclodepsipeptides and to search for new analogues of these compounds. The present manuscript aimed to highlight the extensive variability of cyclodepsipeptides by describing chemistry, biosynthesis, and occurrence of BEAs, ENNs, and BEAEs in foods and feeds. Moreover, the co-occurrence of Fusarium species was compared to the amounts of toxins in crops, vegetables, and fruits from different regions of the world.


Author(s):  
Zhi-Gang Sun ◽  
Liang-Hui Zhao ◽  
Zhi-Na Li ◽  
Hai-Liang Zhu

: The treatment of cancer has always been a major problem in the world. Some cancers cannot be treated with surgery, but only with cancer drugs. Among many cancer drugs, small molecule inhibitors play an irreplaceable role. HER2 is one of the HER family, and the development of HER2 inhibitors has made a huge contribution to the treatment of cancer. Some HER2 inhibitors are already on the market, and some HER2 inhibitors are undergoing clinical research. The design, synthesis and development of new HER2 inhibitors targeting different targets are also ongoing, and some are even applying for clinical research. The HER2 inhibitors that are on the market have developed resistance, which brings great challenges to the HER2 inhibitor development in the future. This article reviews the development and challenges of HER2 inhibitors discovery.


2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 167s-167s
Author(s):  
E.K.d. Santos ◽  
O. Santos ◽  
R.D.S. Reis ◽  
L.D.J.A. Pires ◽  
R. Marques

Background and context: Childhood cancer has low incidence, but it's 1st cause of death by disease from 1-19 years in Brazil. Given the lack of preventive measures, access to early diagnosis and treatment are important control actions. Aim: Elaboration of an advocacy tool based on consolidated data of incidence, mortality and morbidity of childhood cancer in Brazil. Strategy/Tactics: Collaborative work process with specialists: 1) evaluation of previous material, databases, available publications and the public ordinances and norms; 2) extraction and analysis of information, providing contextualized and commented content; 3) disclosure: it's launched annually to celebrate National Childhood Cancer Day, in social networks, media, and also presented at meetings, lectures and congresses for key stakeholders (print and electronic format). Program/Policy process: Consulted sources in 2017 were: national census, national registry of health facilities, mortality information system, cancer mortality atlas, hospital-based cancer registry (HBCR) system, and materials from national institute of cancer and IARC. It's estimated 630 new cases/year for the state of Rio de Janeiro (SRJ), 390 in the metropolitan region and 250 in the capital. Incidence rates in the world, Brazil and SRJ per million were: 140.6; 126.5 and 132 within ages from 0-14 and 185.3; 157.2 and 166 for ages 15-19. The classification of tumor types in Brazil, SRJ and capital were, respectively: 40%, 41% and 39% of nonsolid tumors; 43%, 59% and 61% of solid tumors (from which 28%, 24% and 29% are solid tumors of central nervous system). Total deaths per childhood cancer/week is 1540 in the world, 55 in Brazil and 4 in SRJ, being 2nd cause of death (behind external causes) and 1st cause of death due to illness (7.6%) within ages of 1-19 in Brazil. Authorized hospitals for childhood cancer treatment: 77 units in Brazil and 7 in SRJ, of which 70 and 6 have HBCR, respectively. Only 14 Brazilian units and 1 in ERJ treat a median of > 100 new cases/year. In SRJ, 75% of diagnosed cases started treatment within 15 days, and 15% of adolescents are treated with adults. What was learned: It's needed more involvement of pediatric oncologists and managers in analyzing information and its use in decision making, since many don't use existing databases routinely. Another challenge is to return information to those who register it, and thus help in understanding the working process to qualify and value it through appropriate strategies. Collective construction of consolidated information is an important advocacy tool for health practitioners, managers and even general public: it facilitates understanding the pediatric oncology scenario and exposes opportunities for improvement to deal with incomplete or low-skilled information. Ultimately, it allows and stimulates social control of the entire society, and can be used as support for the planning and alignment of public policies to local problems.[Figure: see text][Figure: see text][Figure: see text]


Author(s):  
S. Vincent Rajkumar

Major advances have occurred in the treatment of multiple myeloma, including several new drugs that typically cost more than $100,000 per year. Although the gains in myeloma therapy improve overall survival considerably, they are available to only a fraction of the population of patients with myeloma in the world because of regulatory barriers and cost. Myeloma is an example of what is happening in cancer on a much larger scale. Many of the problems discussed call for a wider discussion across all cancers, but they are amplified in myeloma because of the need for multidrug regimens that combine three or more expensive new drugs for prolonged periods of time. In this article, the reasons for the high cost of cancer drugs and possible solutions are examined. The lack of correlation of value and price, the remarkable rise in prices of existing old medications over time, and the lack of access to lifesaving drugs across various countries are also discussed.


Sign in / Sign up

Export Citation Format

Share Document